|
|
||||||||
1 Division of Developmental Genetics, National Institute of Genetics, Mishima, Shizuoka, 411-8540, Japan
2 Department of Microbiology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan
3 Department of Genetics, SOKENDAI, Mishima, Shizuoka, 411-8540, Japan
4 CREST, JST, Saitama, 332-0012, Japan
5 Division of Morphology and Organogenesis, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo, 105-8461, Japan
Signaling pathways generally contain multiple negative regulators that are induced by the signal they repress, constructing negative feedback loops. Although such negative regulators are often expressed in a tissue- or cell-type specific manner during development, little is known about the significance of their differential expression patterns and possible interactions. We show the role and interplay of two cell-type specific negative feedback loops during specification of photoreceptor neurons in the Drosophila compound eye, a process that occurs via epidermal growth factor (EGF)-mediated sequential induction through the activation of the Ras/MAPK signaling pathway. Inducing cells secreting EGF express a negative regulator Sprouty (SPRY) that lowers Ras/MAPK signaling activity, and as a consequence reduces the signal-dependent expression of a secreted EGF inhibitor, Argos (AOS). Induced cells in turn express an orphan nuclear receptor Seven-up (SVP), which represses SPRY expression thereby allowing expression and secretion of AOS, preventing further induction. When this intricate system fails, as in spry mutants, sequential induction is no longer constant and the number of photoreceptor neurons becomes variable. Thus, cell-type specific utilization of multiple negative feedback loops not only confers developmental robustness through functional redundancy, but is a key component in generating consistent patterning.
* Correspondence: E-mail: maokabe{at}jikei.ac.jp
This article has been cited by other articles:
![]() |
E. K. Rowinsky Lately, It Occurs to Me What a Long, Strange Trip It's Been for the Farnesyltransferase Inhibitors J. Clin. Oncol., July 1, 2006; 24(19): 2981 - 2984. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | ADVANCED SEARCH | TABLE OF CONTENTS |